TY - JOUR T1 - Genome-wide Association Study of Non-syndromic Orofacial Clefts in a Multiethnic Sample of Families and Controls Identifies Novel Regions JF - medRxiv DO - 10.1101/2020.10.27.20220574 SP - 2020.10.27.20220574 AU - Nandita Mukhopadhyay AU - Eleanor Feingold AU - Lina Moreno-Uribe AU - George Wehby AU - Luz Consuelo Valencia-Ramirez AU - Claudia P. Restrepo Muñeton AU - Carmencita Padilla AU - Frederic Deleyiannis AU - Kaare Christensen AU - Fernando A. Poletta AU - Ieda M Orioli AU - Jacqueline T. Hecht AU - Carmen J. Buxó AU - Azeez Butali AU - Wasiu L. Adeyemo AU - Alexandre R. Vieira AU - John R. Shaffer AU - Jeffrey C. Murray AU - Seth M. Weinberg AU - Elizabeth J. Leslie AU - Mary L. Marazita Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/28/2020.10.27.20220574.abstract N2 - Orofacial clefts (OFCs) are among the most prevalent craniofacial birth defects worldwide and create a significant public health burden. The majority of OFCs are non-syndromic and vary in prevalence by ethnicity. Africans have the lowest prevalence of OFCs (∼ 1/2,500), Asians have the highest prevalence (∼1/500), European and Latin Americans lie somewhere in the middle (∼1/800 and 1/900 respectively). Thus, ethnicity appears to be a major determinant of the risk of developing OFC. The Pittsburgh Orofacial Clefts Multiethnic study was designed to explore this ethnic variance, comprising a large number of families and individuals (∼12,000 individuals) from multiple populations worldwide: US and Europe, Asians, mixed Native American/Caucasians, and Africans. In this current study, we analyzed 2,915 OFC cases, 6,044 unaffected individuals related to the OFC cases, and 2,685 controls with no personal or family history of OFC. Participants were grouped by their ancestry into African, Asian, European, and Central and South American subsets, and genome-wide association run on the combined sample as well as the four ancestry-based groups. We observed 22 associations to cleft lip with or without cleft palate at 18 distinct loci with p-values < 1e-06, including 10 with genome-wide significance (< 5e-08), in the combined sample and within ancestry groups. Three loci - 2p12 (rs62164740, p=6.27e-07), 10q22.2 (rs150952246, p=3.14e-07), and 10q24.32 (rs118107597, p=8.21e-07) are novel. Nine were in or near known OFC loci - PAX7, IRF6, FAM49A, DCAF4L2, 8q24.21, NTN1, WNT3-WNT9B, TANC2, and RHPN2. The majority of the associations were observed only in the combined sample, European, and Central and South American groups. We investigated whether the observed differences in association strength were a) purely due to sample sizes, b) due to systematic allele frequency difference at the population level, or (c) due to the fact certain OFC-causing variants confer different amounts of risk depending on ancestral origin, by comparing effect sizes to observed allele frequencies of the effect allele in our ancestry-based groups. While some of the associations differ due to systematic differences in allele frequencies between groups, others show variation in effect size despite similar frequencies across ancestry groups.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study does not involve clinical trials, and is not a prospective study.Funding StatementThis work was supported by grants from the National Institutes of Health (NIH) including: R01-DE016148 [MLM, SMW], X01-HG007485 [MLM, EF], U01-DE024425 [MLM], R37-DE008559 [JCM, MLM], R21-DE016930 [MLM], R01-DE012472 [MLM], R01-DE011931 [JTH], U01-DD000295 [GLW], R00-DE024571 [CJB], R25-MD007607 [CJB], S21-MD001830 [CJB], U54-MD007587 [CJB], K99/R00 DE022378 [AB]. Genotyping and data cleaning were provided via an NIH/NIDCR contract to the Johns Hopkins Center for Inherited Disease Research: HHSN268201200008I. Additional support provided by an intramural grant from the Research Institute of the Children's Hospital of Colorado [FWD]; additional operating costs support in the Philippines was provided by the Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila [CP].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Pittsburgh Internal Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic and clinical data used in this study is publicly available from dbGaP and the FaceBase repository via the URLs indicated below. http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000774.v2.p1 https://www.facebase.org/chaise/record/#1/isa:dataset/RID=1-50DT?pcid=recordset&ppid=1nel29se1r792mbi23uu1r6t ER -